FY2025 EPS Estimates for DNTH Boosted by Cantor Fitzgerald

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – Research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Dianthus Therapeutics in a report issued on Thursday, March 13th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($3.16) per share for the year, up from their prior estimate of ($3.46). The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The company had revenue of $1.33 million for the quarter, compared to analysts’ expectations of $1.40 million. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%.

DNTH has been the topic of several other research reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Wedbush reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim reaffirmed a “buy” rating and set a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen initiated coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. Finally, Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Dianthus Therapeutics currently has a consensus rating of “Buy” and an average target price of $52.14.

Dianthus Therapeutics Trading Up 0.2 %

DNTH stock opened at $21.33 on Monday. The company has a market capitalization of $631.30 million, a P/E ratio of -8.53 and a beta of 1.82. The firm has a 50 day simple moving average of $22.54 and a 200-day simple moving average of $24.81. Dianthus Therapeutics has a twelve month low of $18.13 and a twelve month high of $33.77.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently modified their holdings of the business. Quest Partners LLC increased its holdings in Dianthus Therapeutics by 112,400.0% in the third quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after purchasing an additional 1,124 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in shares of Dianthus Therapeutics by 142.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 165,929 shares of the company’s stock worth $4,543,000 after buying an additional 97,362 shares during the period. MetLife Investment Management LLC increased its stake in shares of Dianthus Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 13,939 shares of the company’s stock valued at $382,000 after acquiring an additional 7,854 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $821,000. Finally, Braidwell LP boosted its stake in Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after acquiring an additional 126,836 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.